0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Nasal Spray Live Attenuated Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: November 2025
|
Report Code: QYRE-Auto-22F16944
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Nasal Spray Live Attenuated Vaccine Market Research Report 2024
BUY CHAPTERS

Global Nasal Spray Live Attenuated Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-22F16944
Report
November 2025
Pages:134
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Nasal Spray Live Attenuated Vaccine Market

The global Nasal Spray Live Attenuated Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Nasal spray live attenuated vaccine is a live attenuated viral vaccine administered by nasal spray for the prevention of infection against specific diseases. This vaccine injects a weakened live virus into the body through the nasal mucosal route, which activates the immune system to produce a protective immune response against the disease.
From a downstream perspective, Hospitals & Clinics accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Nasal Spray Live Attenuated Vaccine leading manufacturers including AstraZeneca, Sanofi, CSL, BioDiem, SEQIRUS, INC., Changchun BCHT Biotechnology Co., Serum Institute, etc., dominate supply; the top five capture approximately % of global revenue, with AstraZeneca leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Nasal Spray Live Attenuated Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Nasal Spray Live Attenuated Vaccine Market Report

Report Metric Details
Report Name Nasal Spray Live Attenuated Vaccine Market
Segment by Type
  • Trivalent Nasal Spray Live Attenuated Vaccine
  • Quadrivalent Nasal Spray Live Attenuated Vaccine
Segment by Application
  • Hospitals & Clinics
  • Public Health Organizations
  • Research Organizations
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company AstraZeneca, Sanofi, CSL, BioDiem, SEQIRUS, INC., Changchun BCHT Biotechnology Co., Serum Institute
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Nasal Spray Live Attenuated Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Nasal Spray Live Attenuated Vaccine Market report?

Ans: The main players in the Nasal Spray Live Attenuated Vaccine Market are AstraZeneca, Sanofi, CSL, BioDiem, SEQIRUS, INC., Changchun BCHT Biotechnology Co., Serum Institute

What are the Application segmentation covered in the Nasal Spray Live Attenuated Vaccine Market report?

Ans: The Applications covered in the Nasal Spray Live Attenuated Vaccine Market report are Hospitals & Clinics, Public Health Organizations, Research Organizations, Others

What are the Type segmentation covered in the Nasal Spray Live Attenuated Vaccine Market report?

Ans: The Types covered in the Nasal Spray Live Attenuated Vaccine Market report are Trivalent Nasal Spray Live Attenuated Vaccine, Quadrivalent Nasal Spray Live Attenuated Vaccine

1 Study Coverage
1.1 Introduction to Nasal Spray Live Attenuated Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Nasal Spray Live Attenuated Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Trivalent Nasal Spray Live Attenuated Vaccine
1.2.3 Quadrivalent Nasal Spray Live Attenuated Vaccine
1.3 Market Segmentation by Application
1.3.1 Global Nasal Spray Live Attenuated Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals & Clinics
1.3.3 Public Health Organizations
1.3.4 Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Nasal Spray Live Attenuated Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Nasal Spray Live Attenuated Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global Nasal Spray Live Attenuated Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Nasal Spray Live Attenuated Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Nasal Spray Live Attenuated Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Trivalent Nasal Spray Live Attenuated Vaccine Market Size by Manufacturers
3.5.2 Quadrivalent Nasal Spray Live Attenuated Vaccine Market Size by Manufacturers
3.6 Global Nasal Spray Live Attenuated Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Nasal Spray Live Attenuated Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Nasal Spray Live Attenuated Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Nasal Spray Live Attenuated Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Nasal Spray Live Attenuated Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Nasal Spray Live Attenuated Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America Nasal Spray Live Attenuated Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Nasal Spray Live Attenuated Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Nasal Spray Live Attenuated Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe Nasal Spray Live Attenuated Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Nasal Spray Live Attenuated Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Nasal Spray Live Attenuated Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Nasal Spray Live Attenuated Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America Nasal Spray Live Attenuated Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Nasal Spray Live Attenuated Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Nasal Spray Live Attenuated Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.1.4 AstraZeneca Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 AstraZeneca Nasal Spray Live Attenuated Vaccine Sales by Product in 2024
11.1.6 AstraZeneca Nasal Spray Live Attenuated Vaccine Sales by Application in 2024
11.1.7 AstraZeneca Nasal Spray Live Attenuated Vaccine Sales by Geographic Area in 2024
11.1.8 AstraZeneca Nasal Spray Live Attenuated Vaccine SWOT Analysis
11.1.9 AstraZeneca Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.2.4 Sanofi Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Nasal Spray Live Attenuated Vaccine Sales by Product in 2024
11.2.6 Sanofi Nasal Spray Live Attenuated Vaccine Sales by Application in 2024
11.2.7 Sanofi Nasal Spray Live Attenuated Vaccine Sales by Geographic Area in 2024
11.2.8 Sanofi Nasal Spray Live Attenuated Vaccine SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 CSL
11.3.1 CSL Corporation Information
11.3.2 CSL Business Overview
11.3.3 CSL Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.3.4 CSL Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 CSL Nasal Spray Live Attenuated Vaccine Sales by Product in 2024
11.3.6 CSL Nasal Spray Live Attenuated Vaccine Sales by Application in 2024
11.3.7 CSL Nasal Spray Live Attenuated Vaccine Sales by Geographic Area in 2024
11.3.8 CSL Nasal Spray Live Attenuated Vaccine SWOT Analysis
11.3.9 CSL Recent Developments
11.4 BioDiem
11.4.1 BioDiem Corporation Information
11.4.2 BioDiem Business Overview
11.4.3 BioDiem Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.4.4 BioDiem Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 BioDiem Nasal Spray Live Attenuated Vaccine Sales by Product in 2024
11.4.6 BioDiem Nasal Spray Live Attenuated Vaccine Sales by Application in 2024
11.4.7 BioDiem Nasal Spray Live Attenuated Vaccine Sales by Geographic Area in 2024
11.4.8 BioDiem Nasal Spray Live Attenuated Vaccine SWOT Analysis
11.4.9 BioDiem Recent Developments
11.5 SEQIRUS, INC.
11.5.1 SEQIRUS, INC. Corporation Information
11.5.2 SEQIRUS, INC. Business Overview
11.5.3 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.5.4 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Sales by Product in 2024
11.5.6 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Sales by Application in 2024
11.5.7 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine Sales by Geographic Area in 2024
11.5.8 SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine SWOT Analysis
11.5.9 SEQIRUS, INC. Recent Developments
11.6 Changchun BCHT Biotechnology Co.
11.6.1 Changchun BCHT Biotechnology Co. Corporation Information
11.6.2 Changchun BCHT Biotechnology Co. Business Overview
11.6.3 Changchun BCHT Biotechnology Co. Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.6.4 Changchun BCHT Biotechnology Co. Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Changchun BCHT Biotechnology Co. Recent Developments
11.7 Serum Institute
11.7.1 Serum Institute Corporation Information
11.7.2 Serum Institute Business Overview
11.7.3 Serum Institute Nasal Spray Live Attenuated Vaccine Product Models, Descriptions and Specifications
11.7.4 Serum Institute Nasal Spray Live Attenuated Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Serum Institute Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Nasal Spray Live Attenuated Vaccine Industry Chain
12.2 Nasal Spray Live Attenuated Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Nasal Spray Live Attenuated Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Nasal Spray Live Attenuated Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Nasal Spray Live Attenuated Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Nasal Spray Live Attenuated Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
 Table 1. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Nasal Spray Live Attenuated Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Nasal Spray Live Attenuated Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Nasal Spray Live Attenuated Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
 Table 7. Global Nasal Spray Live Attenuated Vaccine Sales by Region (2020-2025) & (K Dose)
 Table 8. Global Nasal Spray Live Attenuated Vaccine Sales by Region (2026-2031) & (K Dose)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Nasal Spray Live Attenuated Vaccine Sales by Manufacturers (2020-2025) & (K Dose)
 Table 11. Global Nasal Spray Live Attenuated Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global Nasal Spray Live Attenuated Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Nasal Spray Live Attenuated Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nasal Spray Live Attenuated Vaccine as of 2024)
 Table 16. Global Nasal Spray Live Attenuated Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Nasal Spray Live Attenuated Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
 Table 18. Key Manufacturers Nasal Spray Live Attenuated Vaccine Manufacturing Base and Headquarters
 Table 19. Global Nasal Spray Live Attenuated Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Nasal Spray Live Attenuated Vaccine Sales by Type (2020-2025) & (K Dose)
 Table 23. Global Nasal Spray Live Attenuated Vaccine Sales by Type (2026-2031) & (K Dose)
 Table 24. Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Nasal Spray Live Attenuated Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Nasal Spray Live Attenuated Vaccine ASP by Type (2020-2031) & (US$/Dose)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Nasal Spray Live Attenuated Vaccine Sales by Application (2020-2025) & (K Dose)
 Table 29. Global Nasal Spray Live Attenuated Vaccine Sales by Application (2026-2031) & (K Dose)
 Table 30. Nasal Spray Live Attenuated Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Nasal Spray Live Attenuated Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Nasal Spray Live Attenuated Vaccine ASP by Application (2020-2031) & (US$/Dose)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Nasal Spray Live Attenuated Vaccine Growth Accelerators and Market Barriers
 Table 37. North America Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Nasal Spray Live Attenuated Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales (K Dose) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Nasal Spray Live Attenuated Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Nasal Spray Live Attenuated Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Nasal Spray Live Attenuated Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. AstraZeneca Corporation Information
 Table 51. AstraZeneca Description and Major Businesses
 Table 52. AstraZeneca Product Models, Descriptions and Specifications
 Table 53. AstraZeneca Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 54. AstraZeneca Sales Value Proportion by Product in 2024
 Table 55. AstraZeneca Sales Value Proportion by Application in 2024
 Table 56. AstraZeneca Sales Value Proportion by Geographic Area in 2024
 Table 57. AstraZeneca Nasal Spray Live Attenuated Vaccine SWOT Analysis
 Table 58. AstraZeneca Recent Developments
 Table 59. Sanofi Corporation Information
 Table 60. Sanofi Description and Major Businesses
 Table 61. Sanofi Product Models, Descriptions and Specifications
 Table 62. Sanofi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 63. Sanofi Sales Value Proportion by Product in 2024
 Table 64. Sanofi Sales Value Proportion by Application in 2024
 Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 66. Sanofi Nasal Spray Live Attenuated Vaccine SWOT Analysis
 Table 67. Sanofi Recent Developments
 Table 68. CSL Corporation Information
 Table 69. CSL Description and Major Businesses
 Table 70. CSL Product Models, Descriptions and Specifications
 Table 71. CSL Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 72. CSL Sales Value Proportion by Product in 2024
 Table 73. CSL Sales Value Proportion by Application in 2024
 Table 74. CSL Sales Value Proportion by Geographic Area in 2024
 Table 75. CSL Nasal Spray Live Attenuated Vaccine SWOT Analysis
 Table 76. CSL Recent Developments
 Table 77. BioDiem Corporation Information
 Table 78. BioDiem Description and Major Businesses
 Table 79. BioDiem Product Models, Descriptions and Specifications
 Table 80. BioDiem Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 81. BioDiem Sales Value Proportion by Product in 2024
 Table 82. BioDiem Sales Value Proportion by Application in 2024
 Table 83. BioDiem Sales Value Proportion by Geographic Area in 2024
 Table 84. BioDiem Nasal Spray Live Attenuated Vaccine SWOT Analysis
 Table 85. BioDiem Recent Developments
 Table 86. SEQIRUS, INC. Corporation Information
 Table 87. SEQIRUS, INC. Description and Major Businesses
 Table 88. SEQIRUS, INC. Product Models, Descriptions and Specifications
 Table 89. SEQIRUS, INC. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 90. SEQIRUS, INC. Sales Value Proportion by Product in 2024
 Table 91. SEQIRUS, INC. Sales Value Proportion by Application in 2024
 Table 92. SEQIRUS, INC. Sales Value Proportion by Geographic Area in 2024
 Table 93. SEQIRUS, INC. Nasal Spray Live Attenuated Vaccine SWOT Analysis
 Table 94. SEQIRUS, INC. Recent Developments
 Table 95. Changchun BCHT Biotechnology Co. Corporation Information
 Table 96. Changchun BCHT Biotechnology Co. Description and Major Businesses
 Table 97. Changchun BCHT Biotechnology Co. Product Models, Descriptions and Specifications
 Table 98. Changchun BCHT Biotechnology Co. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 99. Changchun BCHT Biotechnology Co. Recent Developments
 Table 100. Serum Institute Corporation Information
 Table 101. Serum Institute Description and Major Businesses
 Table 102. Serum Institute Product Models, Descriptions and Specifications
 Table 103. Serum Institute Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
 Table 104. Serum Institute Recent Developments
 Table 105. Key Raw Materials Distribution
 Table 106. Raw Materials Key Suppliers
 Table 107. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 108. Milestones in Production Technology Evolution
 Table 109. Distributors List
 Table 110. Market Trends and Market Evolution
 Table 111. Market Drivers and Opportunities
 Table 112. Market Challenges, Risks, and Restraints
 Table 113. Research Programs/Design for This Report
 Table 114. Key Data Information from Secondary Sources
 Table 115. Key Data Information from Primary Sources


List of Figures
 Figure 1. Nasal Spray Live Attenuated Vaccine Product Picture
 Figure 2. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Trivalent Nasal Spray Live Attenuated Vaccine Product Picture
 Figure 4. Quadrivalent Nasal Spray Live Attenuated Vaccine Product Picture
 Figure 5. Global Nasal Spray Live Attenuated Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospitals & Clinics
 Figure 7. Public Health Organizations
 Figure 8. Research Organizations
 Figure 9. Others
 Figure 10. Nasal Spray Live Attenuated Vaccine Report Years Considered
 Figure 11. Global Nasal Spray Live Attenuated Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 13. Global Nasal Spray Live Attenuated Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Region (2020-2031)
 Figure 15. Global Nasal Spray Live Attenuated Vaccine Sales (2020-2031) & (K Dose)
 Figure 16. Global Nasal Spray Live Attenuated Vaccine Sales (CAGR) by Region (2020-2031) (K Dose)
 Figure 17. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Region (2020-2031)
 Figure 18. Top 5 and Top 10 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Volume Market Share in 2024
 Figure 19. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. Trivalent Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturer in 2024
 Figure 22. Quadrivalent Nasal Spray Live Attenuated Vaccine Revenue Market Share by Manufacturer in 2024
 Figure 23. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Type (2020-2031)
 Figure 24. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Type (2020-2031)
 Figure 25. Global Nasal Spray Live Attenuated Vaccine Sales Market Share by Application (2020-2031)
 Figure 26. Global Nasal Spray Live Attenuated Vaccine Revenue Market Share by Application (2020-2031)
 Figure 27. North America Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 28. North America Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. North America Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 30. North America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2020- 2031)
 Figure 31. North America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 32. North America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 33. North America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 34. US Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 35. Canada Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 36. Mexico Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 37. Europe Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 38. Europe Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Europe Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 40. Europe Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2020-2031)
 Figure 41. Europe Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Europe Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 43. Europe Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Germany Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 45. France Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. U.K. Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. Italy Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 48. Russia Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 50. Asia-Pacific Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 51. Asia-Pacific Top 8 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 52. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2020- 2031)
 Figure 53. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 54. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 55. Asia-Pacific Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Indonesia Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 57. Japan Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. South Korea Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. China Taiwan Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 60. India Nasal Spray Live Attenuated Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 61. Central and South America Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 62. Central and South America Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Central and South America Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 64. Central and South America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2021-2031)
 Figure 65. Central and South America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Central and South America Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 67. Central and South America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 68. Brazil Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 69. Argentina Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 70. Middle East, and Africa Nasal Spray Live Attenuated Vaccine Sales YoY (2020-2031) & (K Dose)
 Figure 71. Middle East and Africa Nasal Spray Live Attenuated Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 72. Middle East and Africa Top 5 Manufacturers Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) in 2024
 Figure 73. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Type (2021-2031)
 Figure 74. South America Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 75. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Volume (K Dose) by Application (2020-2031)
 Figure 76. Middle East and Africa Nasal Spray Live Attenuated Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 77. GCC Countries Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 78. Turkey Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. Egypt Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 80. South Africa Nasal Spray Live Attenuated Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 81. Nasal Spray Live Attenuated Vaccine Industry Chain Mapping
 Figure 82. Regional Nasal Spray Live Attenuated Vaccine Manufacturing Base Distribution (%)
 Figure 83. Global Nasal Spray Live Attenuated Vaccine Production Market Share by Region (2020-2031)
 Figure 84. Nasal Spray Live Attenuated Vaccine Production Process
 Figure 85. Regional Nasal Spray Live Attenuated Vaccine Production Cost Structure
 Figure 86. Channels of Distribution (Direct Vs Distribution)
 Figure 87. Bottom-up and Top-down Approaches for This Report
 Figure 88. Data Triangulation
 Figure 89. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Samsung SD